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Abstract A serum biomarker (FibroTest; Biopredictive,
Paris, France; FibroSure; LabCorp, Burlington, USA) and
liver stiffness measurement (LSM) by Fibroscan (Echosens,
Paris, France) have been extensively validated in chronic
hepatitis C. This review updates the clinical validation of
serum biomarkers and LSM in patients with chronic hepatitis
B (CHB). One meta-analysis combined all published studies
and another used a database combining FibroTest individual
data. Sensitivity analysis assessed the impact of several
factors, including authors’ independence, length of biopsy,
ethnicity, hepatitis B early antigen status, viral load, and
alanine aminotransferase value. Only two biomarkers had
several validations: FibroTest (8 studies, 1,842 patients), and
Fibroscan (5 studies, 618 patients). For the diagnosis of
advanced fibrosis, the standardized area under the receiver
operating curve was 0.84 (0.79–0.86) for FibroTest and 0.89
(0.83–0.96) for LSM, without significant difference. No
significantfactorsofvariabilitywereidentifiedforFibroTest’s
performance. In conclusion, FibroTest and LSM were the
most validated biomarkers of fibrosis in CHB. However, the
reliability of Fibroscan must be better assessed.
Keywords Fibrosis biomarkers.Meta-analysis.
Obuchowski measure.FibroTest.FibroSure.FibroScan.
Biopsy.Elastography
Introduction
The “gold standard” reference for determining hepatic
histology in chronic hepatitis B (CHB) used to be liver biopsy.
Because of the limitations of liver biopsy, however, several
noninvasive biomarkers have been validated since 2001.
Between 2001 and 2008, two techniques—as e r u m
biomarker (FibroTest; Biopredictive, Paris, France; Fibro-
Sure; LabCorp, Burlington, USA) and liver stiffness mea-
surement (LSM) (Fibroscan; Echosens, Paris, France)—were
extensively validated using biopsy, and six other biomarkers
also were investigated but withfewer studies:Enhanced Liver
Fibrosis (ELF) test, Fibrometer, Fibrospect, FIB-4 (age,
platelets, aspartate aminotransferase [AST] and alanine
aminotransferase [ALT]), Hepascore, and APRI (AST-to-
platelet ratio index) [1]. According to meta-analyses, most of
these studies were initially published in patients with chronic
hepatitis C (CHC). In eight previous meta-analyses published
b e t w e e n2 0 0 2a n d2 0 0 8[ 2–9], only FibroTest had been
validated in five studies including only patients with CHB [10–
13, 14￿]. No meta-analysis was possible for other biomarkers.
Unlike CHC [7], no guidelines recommend biomarkers
for routine clinical use in patients with CHB, although
“they might be helpful on a case-by-case basis” [15￿￿].
The primary objective of this review is to update the last
published meta-analyses on the clinical validation of serum
biomarkers and LSM in the management of patients with
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and the new recommended Obuchowski measures to
prevent spectrum effect and multiple testing [16￿￿], and
we searched for prognostic studies.
Methods
This study was conducted according to the principles
expressed in the Declaration of Helsinki. Two meta-
analyses were performed: one combined all identified
published studies, and the other used an integrated database
combining individual data provided by authors.
Design of Meta-Analysis of Published Studies
The primary outcome was the differentiation of nonadvanced
fibrosis from advanced fibrosis, defined using the METAVIR
scoring system (F0–F1 vs F2–F4) [17]. We chose this
endpoint because it seems at least as rational as the viral
load to assess the severity of CHB [15￿￿, 18￿￿]. The other
endpoints were the performance for the diagnosis of cirrhosis
and the prognostic values.
To select published studies, we used the Standards for
Reporting of Diagnostic Accuracy (STARD) criteria and the
Cochrane Database of Systematic Reviews (CDSR) methods
[19]. Key STARD criteria include factors such as whether
(1) the study population was relevant to the clinical question
being addressed; (2) there was a careful description of the
population from which the patients were drawn, as well as
actual inclusions and exclusions; (3) recruitment and the
mode of sampling were carefully described; (4) researchers
interpreting the noninvasive test were blinded to the
reference test result; and (5) sufficient data were provided
to complete a 2×2 table of true and false positive and
negative diagnoses. Studies published only with an abstract
provided insufficient data and were excluded.
Search Strategy
We searched MEDLINE with the keywords “HBV,
Fibrosis, FibroTest, Fibroscan, Elastography, ELF, Fibro-
spect, and Hepascore.” We hand-searched key journals
(Gastroenterology, Hepatology, Journal of Hepatology,
Gut, Journal of Viral Hepatitis,a n dAmerican Journal of
Gastroenterology) from February 2001 to December 2010
to validate the search, as well as the references of
publications identified by previous searches.
Inclusion and Exclusion Criteria
We excluded all studies except those that included patients
with CHB; stated that all patients had had the biomarker and
liver biopsy; provided data for true positives and negatives,
false positives and negatives, and area under the receiver
operating curves (AUROCs) for advanced fibrosis; stated that
thebiomarkerhadbeenassessedblindtothebiopsy;andstated
the method used for defining the degree of fibrosis. We were
careful to avoid including data from duplicate publications. We
excluded the following biomarkers, which combined ALT or
AST in their formula with a risk of confounding impact of
necro-inflammatory histologic activity on the fibrosis stage
estimates: Fibrometer, FIB-4, and APRI [20–22].
Statistical Methods Used in AUROCs Meta-Analysis
Meta-analysis was performed twice, once according to the
absolute value of the not-standardized AUROCs (AUROC)
and once according to the AUROCs standardized for the
spectrum of fibrosis stages (StAUROC). We previously
demonstrated that the AUROCs were highly related to the
Difference between Advanced and Non Advanced mean
fibrosis stages (DANA); the StAUROC is the AUROC
adjusted for the difference of the observed DANA versus a
standard DANA of 2.5 fibrosis METAVIR units (DANA =
2.5, if there was a uniform prevalence of 0.20 in each of the
five stages). The regression between the AUROCs and the
whole DANA spectrum of published studies in CHB enables
the AUROC to be estimated from the DANA. The regression
formula for standardizing AUROCs estimated from different
stage prevalences, according to previously published method
and to the identified biomarkers, was: StAUROC ¼
AUROC þ 0:0482   2:5DANA ðÞ [20, 23￿￿].
The AUROC was estimated by the empirical (nonpara-
metric) methodofDelongetal.[24], equivalent to the Mann–
Whitney statistic, and compared using the paired method of
Zhou et al. [25]. The meta-analysis was stratified according
to the biomarkers. The analysis used a random effect model,
and the heterogeneity between effects according to publica-
tions and biomarkers was tested using Cochran’sQ
heterogeneity test. A sensitivity analysis was also performed
according to the independence of authors for FibroTest.
Design of Individual Data Meta-Analysis
Patients
Patients with individual data included in the database were
described in a previous overview of FibroTest in patients
with chronic liver diseases [8]. For the present study, only
patients with hepatitis B virus (HBV) were included.
Patients’ data were included with the agreement of authors
in the present study if they met the following optimal
conditions of analyses: they must have been included in a
validation study including FibroTest, ALT, and biopsy with
METAVIR scoring system for fibrosis score, according to
88 Curr Hepatitis Rep (2011) 10:87–97preanalytical and analytical recommendations. All patients
have CHB with positive polymerase chain reaction test. All
biomarkershavebeenassessedblindedtoclinical,biochemical,
or histologic patient characteristics.
Biochemical Analysis
The dosage methods for each of the FibroTest parameters
followed the standardized conditions, as listed in the technical
recommendations (http://www.biopredictive.com).
Liver Biopsies
Liver biopsies were processed using standard techniques. A
pathologist who was unaware of the biomarkers evaluated the
fibrosis stage according to the METAVIR scoring system [17].
Fibrosis was staged on a scale of 0 to 4: F0—no fibrosis; F1—
portal fibrosis without septa; F2—few septa; F3—numerous
septa without cirrhosis; and F4—cirrhosis. Biopsies were
performed with a 16-gauge Hepafix Luer-Lock needle (Braun
Melsungen, Melsungen, Germany) in the Paris center, and
with various needles in the multicenter study from Marseille.
Statistical Analysis of Integrated Database
The use of the AUROC raises two methodologic issues.
First, its use is based on the assumption that the gold
standard is binary, whereas fibrosis staging uses an ordinal
scale. This difference implies that fibrosis stages in the
study sample have to be aggregated into two groups, a
process that can lead to discordant conclusions, depending
on how the groups are aggregated [16￿￿, 20, 22]. Analysis
based on the AUROC can also be biased by the way in
which the proportion of each stage of fibrosis in the sample
fits the distribution in the reference population to which the
indices are applied. As a result, the comparison of different
AUROCs based on samples with different stage distribu-
tions may be flawed (spectrum effect) [16￿￿, 20, 22, 23￿￿].
The spectrum effect reflects the inherent variation in test
performance among population subgroups. Subgroup vari-
ation is not a bias, but is clinically relevant information to
be identified and reported with appropriate analyses. If a
spectrum effect is possible, heterogeneity should be
assessed by subgroup analyses of test performance.
Toovercomethesemethodologicissues,twomethodswere
recently proposed and validated for fibrosis staging and
activity grading in patients with CHC. We proposed a
standardization of the AUROC for the distribution of fibrosis
stages to deal with the spectrum effect [20, 23￿￿]. Lambert et
al. [16￿￿] proposed using the Obuchowski measure to
overcome both spectrum effect and ordinal scale. This
measure can be used in situations in which the gold standard
is not binary. Furthermore, the Obuchowski measure allows
comparison of two biomarkers with a single test, avoiding
appropriate correction for the type 1 error when comparing
two biomarkers for different stages or grades [16￿￿, 22].
Obuchowski Measure
The Obuchowski measure is a multinomial version of the
AUROC. With N (=5) categories of the gold standard
outcome (histologic activity grade) and AUROCst (the
estimate of the AUROC of diagnostic tests for differenti-
ating between categories s and t), the Obuchowski measure
is a weighted average of the NN  1 ðÞ =2 ¼ 10 ðÞ different
AUROCst corresponding to all the pairwise comparisons
between two of the N categories.
Each pairwise comparison was weighted to take into
account the distance between activity grades (ie, the number
of units on the ordinal scale). A penalty function proportional
to the difference in METAVIR units between grades was
defined: the penalty function was 0.25 when the difference
between stages was 1; 0.50 when the difference between
stages was 2; 0.75 when the difference was 3; and 1 when the
differencewas4.TheObuchowskimeasurecanbeinterpreted
as the probability that the noninvasive index will correctly
rank two randomly chosen patient samples from different
fibrosis stages according to the weighting scheme, with a
penalty for misclassifying patients. Note that the overall
Obuchowski measure is not equivalent to a usual AUROC
curve, because the measurements are weighted according to
the distance between stages. The FibroTest cutoffs were those
recommended by the manufacturer since the first validation
using biopsy: 0.27 for F1, 0.48 for F2, and 0.58 for F3 and
0.74 for F4 [20]. For ALT, the a priori simple cutoffs chosen
were 25, 50, 75, and 100 IU/L, because we previously
demonstrated that the expression of ALT activity using the
upper limit of normal was hazardous [26].
Main Endpoint
The main endpoint was the accuracy estimated with
Obuchowski measure. The FibroTest accuracy was
compared with ALT, a standard marker of liver disease
severity in CHB [15￿￿].
Sensitivity Analyses
Sensitivity analyses were performed in the integrated
database by comparing FibroTest performances according
to the variability factors: gender, biopsy length [27],
ethnicity, hepatitis B early antigen (HBeAg) status, HBV
genotype, viral load, and ALT value. In one study, patients
were included twice, because they had FibroTest and
biopsy once before and once after the treatment; a
sensitivity analysis was performed comparing patients
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suspected (P<0.10) between nonstandardized AUROCs
for advanced fibrosis, Obuchowski measures were assessed.
Each estimate was given with its 95% confidence interval
(95% CI). Analyses were performed on NCSS software
(Kaysville, Utah, USA) [28]a n do nRs o f t w a r e[ 29].
Results
Databases
The search retrieved 42 references: 22 for FibroTest, 17 for
LSM,twoforHepascore,andone forELFscore.Fromthe41,
17 were pre-included as original diagnostic studies including
only CHB, and 15 studies fully satisfied the inclusion criteria
(Table 1). Only one prognostic study was identified [18￿￿].
ForFibroTest,eightstudieswerepre-included,andallwere
included for not-standardized meta-analysis for advanced
fibrosis. Since the previous meta-analysis, three new studies
were included [30–32]. One study was not included in the
standardized meta-analysis because it did not provide
prevalence of each fibrosis stage [30]. One study did not
provide data for cirrhosis [11].
For LSM measured by FibroScan, six studies were pre-
included and five were included for meta-analysis [33–37]. One
was excluded because it did not provide AUROC [37], and one
was not included in the standardized meta-analysis because it
did not provide prevalence of each fibrosis stage [35].
For Hepascore, two studies were pre-included and both
included in the meta-analysis (Table 1)[ 31, 38].
For the integrated database, we excluded six patients
with acute hepatitis suspected by security algorithms [8],
explaining differences in the total number of subjects
between integrated database (n=1,303) and the published
studies (n=1,309) [10, 11].
Comparison Between Biomarker Performances According
to Published Studies
Diagnosis of Advanced Fibrosis
Not-standardized AUROCs were all significantly higher than
the random 0.50 value (P<0.001). Mean AUROC was 0.80
(95% CI, 0.77–0.82). There was no significant difference
among performance of the three biomarkers: FibroTest
AUROC = 0.79 (0.76–0.82), HepaScore AUROC = 0.75
(0.66–0.84), and LSM AUROC = 0.84 (0.78–0.89). There
was no significant heterogeneity between studies (Cochran
heterogeneity test = 9.5, P=0.80).
Standardized AUROCs, taking into account the spectrum
of fibrosis stages, were all significantly higher than the
random 0.50 value (P<0.001) (Fig. 1). Mean StAUROC
was 0.84 (95% CI, 0.80–0.87). There was no significant
difference among the performance of the three biomarkers:
FibroTest StAUROC = 0.84 (0.79–0.86), HepaScore
StAUROC = 0.80 (0.71–0.89), and LSM StAUROC = 0.89
(0.83–0.96). There was no significant heterogeneity between
studies (Cochran heterogeneity test = 6.3, P=0.90).
Diagnosis of Cirrhosis
Not-standardized AUROCs were all significantly higher than
the random 0.50 value (P<0.001). Mean AUROC was 0.87
(95% CI, 0.82–0.91). There was no significant difference
among the performance of the three biomarkers: FibroTest
AUROC = 0.83 (0.78–0.87), HepaScore AUROC = 0.86
(0.74–0.98), and LSM AUROC = 0.93 (0.87–0.99). There
was no significant heterogeneity between studies (Cochran
heterogeneity test = 15.1, P=0.13).
Standardized AUROCs, taking into account the spectrum
of fibrosis stages, were all significantly higher than the
random 0.50 value (P<0.001). Mean StAUROC was 0.89
(95% CI, 0.85–0.92). There was no significant difference
among the performance of the three biomarkers: FibroTest
StAUROC = 0.85 (0.80–0.90), HepaScore StAUROC = 0.88
(0.76–1.00), and LSM StAUROC = 0.96 (0.90–1.00). There
was no significant heterogeneity between studies (Cochran
heterogeneity test = 16.6, P=0.09).
Sensitivity Analysis
There was no difference between the performances of
FibroTest according to the independence of authors. The
not-standardized AUROC for advanced fibrosis was 0.83
(0.78–0.87) for the four independent publications and 0.77
(0.73–0.81) for the four dependent publications. The other
performances were also not significant (data not shown).
FibroTest’s Performance According to Individual Data
Meta-Analysis (Table 2)
Performance Between All Fibrosis Stages
The overall mean (95% CI) accuracy of FibroTest
(Obuchowski measure) was 0.844 (0.832–0.856), greater
than that of ALT, which was 0.803 (0.791–0.815), P<0.0001.
FibroTest’s performances were particularly greater than those
of ALT for the diagnosis between F0 and F1 (0.61 [0.56–
0.66] vs 0.52 [0.46–0.58]) and between F3 and F4 (0.58
[0.52–0.64] vs 0.50 [0.44–0.56]).
Sensitivity Analyses
Using not-standardized AUROC, FibroTest had a lower
performance in patients without HBeAg (0.73 [0.68–0.77])
90 Curr Hepatitis Rep (2011) 10:87–97versus patients with HBeAg (0.78 [0.75–0.82]; P=0.046),
and in Asian patients (0.72 [0.67–0.76]) versus non-Asian
patients (0.78 [0.74–0.82]). These differences were no more
significant using Obuchowski measures: 0.831 (0.814–
0.848) versus 0.854 (0.838–0.870; P>0.10) for HBeAg
status, and 0.836 (0.814–0.848) versus 0.853 (0.839–0.867;
P>0.10) for ethnicity (Table 2). All the other characteristics
were not associated with significant variability in the
performances of FibroTest.
Prognostic Value of Fibrosis Biomarkers in CHB
Only one published study was identified concerning
FibroTest [18￿￿]. The first aim of this study was to compare
the 4-year prognostic value of FibroTest and ActiTest to
that of viral load and to that of biopsy (in a subpopulation
with simultaneous biopsy). The second aim of the study
was to compare the 4-year prognostic value of combining
FibroTest, ActiTest, and viral load for a better definition of
the inactive HBV carrier status.
The main endpoint was the absence of liver-related
complications. Liver-related complications were defined
as death, liver transplantation, or one of the following:
decompensation (ascites, hepatic encephalopathy, or
jaundice with total bilirubin >51 μmol/L), variceal
bleeding, or hepatocellular carcinoma. The adjustment
factors were age, sex, HBeAg, ethnic origin, alcohol
consumption, HIV-Delta-hepatitis C virus coinfection,
and treatment.
The study included 1,074 patients with baseline FibroTest,
ActiTest, and viral load (41 years old, 69% male, 47%
African, 27% Asian, 20% Caucasian, 15.5% coinfected,
mean follow-up 7.7 years [2.5 years prospective and 5.2 years
retrospective]). Manufacturers’ definitions were used for
normal FibroTest (≤0.27), and normal ActiTest (≤0.29).
The prevalences of a three-class viral load in international
units per milliliter (low = <log 3, intermediate = log 3–log 5,
high = >log 5) were 55%, 28%, and 17%, respectively. The
accuracy (AUROC [95% CI]) of FibroTest in 97 patients
with simultaneous liver biopsies for the diagnosis of
advanced fibrosis was similar to previous validations
(AUROC=0.83 [0.71–0.91]), and higher than ALT (0.60
[0.47–0.71]) and viral load (0.53 [0.39–0.63]) (all P<
0.0001), and not different from liver biopsy (P=ns).
At 4-years’ follow-up, 50 complications occurred (sur-
vival without complications was 93.4%) and 36 deaths
(survival was 95.0%), including 27 related to HBV
(survival was 96.1%). The prognostic value of FibroTest
was higher than that of viral load or ALT when compared
using AUROC curves (all P<0.0001), survival curves, and
multivariate Cox model. Among the 336 patients (without
coinfection with hepatitis C virus, Delta, or HIV) with the
classic definition of inactive carrier, 74 (22%) had advanced
fibrosis presumed with FibroTest, and three died or had
complications at 4 years’ follow-up. A new definition of
inactive carriers was proposed, with an algorithm
combining “zero” scores for FibroTest and ActiTest (F0
and A0) and viral load classes. This new algorithm provided a
100% negative predictive value for the prediction of liver-
related complications or death at 4 years.
Discussion
This overview largely confirmed in patients with CHB the
diagnostic performance of FibroTest and LSM by Fibroscan,
which was alreadyextensivelyvalidated inpatientswithCHC
[1–10]. These performances were highly significant both for
the diagnosis of advanced fibrosis and for the diagnosis of
cirrhosis. The other fibrosis biomarkers have been less
studied, preventing any conclusions. Only two studies have
been identified for Hepascore, but the performances were
also similar to those in patients with CHC.
Strength of the Study
The methodology of the present overview permitted taking
into account the spectrum effect in the assessment of
performances and identification of factors associated with
variability. The same biomarker can have an AUROC of
0.87 for discriminating stages from F0 to F4 and an
AUROC of 0.51 for discriminating between stages F1 and
F2 (Table 1). As in patients with CHC, there was a clear
risk of misleading conclusions if biomarkers were indirectly
compared without standardizations on fibrosis spectrum.
The Obuchowski method permitted validation of the higher
performance of FibroTest versus ALT for the diagnosis of
fibrosis stages.
The methods permitted accounting for the spectrum
variability between Asian and non-Asian patients as well as
between HBeAg-positive and HBeAg-negative patients.
There was also no impact of the authorship with same
FibroTest performances among independent and not-
independent publications.
Limits of the Study
Reliability of Biomarkers
The present overview was not designed to assess the
failure rate and the reliability rate of the biomarkers,
which are a main concern in the clinical performance.
From recent large studies, LSM has a weakness in
comparison to serum biomarkers, with a 3.1% failure
rate and 15.8% unreliable results [39￿￿,40￿], compared to
0% failure for FibroTest and less than 5% unreliable
Curr Hepatitis Rep (2011) 10:87–97 91T
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Curr Hepatitis Rep (2011) 10:87–97 93results [8]. The most frequent causes of unreliable results
for Fibroscan are necro-inflammatory activity flares and
metabolic factors, and for FibroTest, hemolysis and acute
inflammation [8, 39￿￿, 40￿].
Individual Data
Another weakness was to have only individual data for
FibroTest and not for LSM. Only the analysis of large
databases can identify sources of variability in the
diagnostic performances of biomarkers [20, 41￿￿], including
the variability of biopsy, the imperfect gold standard [27].
The mean length of biopsy was small in the present
studies (usually <20 mm), including in the individual
database (15 mm), and it was reassuring that the
performances of Fibrotest were stable in the sensitivity
analysis. Furthermore, standardization of AUROCs
requires individual data, both for using DANA correc-
tion and Obuchowski measures [16￿￿, 22, 23￿￿].
Absence of a True Gold Standard
Because of the limitations of biopsy, even with 25-mm
length, a need exists to improve the assessment of liver
biomarker performances using methods without gold stan-
dards [41￿￿, 42, 43￿]. No latent class analyses have been
performed in CHB, and only one study has demonstrated
the prognostic value of FibroTest in CHB [18￿￿], confirm-
ing those already observed in patients with CHC [43￿] and
alcoholic liver disease [44￿].
Conclusions
This overview suggests that FibroTest and Fibroscan could be
used as an alternative to liver biopsy in patients with CHB.
However, for Fibroscan, a large analysis of individual data
using Obuchowski measures seems necessary to assess the
impact of necroinflammatory activity grades and steatosis,
Fig. 1 Meta-analysis of the area
under the receiver operating
curve (AUROC) observed in
published studies of Fibrotest,
HepaScore, and liver stiffness
measurement (LSM) for the
diagnosis of advanced fibrosis in
patients with chronic hepatitis
B. Standardized AUROCs
(StAUROCs), taking into
account the spectrum of fibrosis
stages, were all significantly
higher than the random 0.50
value (P<0.001). Mean
StAUROC was 0.84 (95% CI,
0.80–0.87). There was no
significant difference among
performance of the three
biomarkers: FibroTest
StAUROC = 0.84 (0.79–0.86),
HepaScore StAUROC = 0.80
(0.71–0.89), and LSM
StAUROC = 0.89 (0.83–0.96).
There was no significant
heterogeneity between studies
(Cochran heterogeneity
test = 6.3, P=0.90)
94 Curr Hepatitis Rep (2011) 10:87–97Table 2 Sensitivity analyses of FibroTest diagnostic values according to patient characteristics
Advanced fibrosis Pairwise comparisons between all
stages, Obuchowski measure
Characteristic (no. of patients) Not standardized AUROC Significance (P) AUROC (95% CI)
All (1303) 0.76 (0.73–0.79) 0.844 (0.832–0.856)
Gender >0.10
Male (941) 0.75 (0.72–0.78)
Female (362) 0.76 (0.70–0.81)
Length of biopsy >0.10
<25 mm (942) 0.76 (0.71–0.85)
≥25 mm (148) 0.79 (0.71–0.85)
Not available (213) 0.76 (0.69–0.82)
Ethnicity
a 0.06 P>0.10
Asian (546) 0.72 (0.67–0.76) 0.836 (0.814–0.848)
Caucasian (601) 0.78 (0.74–0.82) 0.853 (0.839–0.867)
Sub-Saharan (156)
b 0.80 (0.72–0.86)
HBeAg
c,d 0.046 P>0.10
Absent (548) 0.73 (0.68–0.77)
e 0.854 (0.838–0.870)
Present (753) 0.78 (0.75–0.82) 0.831 (0.814–0.848)
After treatment >0.10
No (723) 0.75 (0.71–0.78)
Yes (392) 0.78 (0.72–0.82)
Not available (188) 0.78 (0.70–0.85)
HBV genotype >0.10
Genotype A (61) 0.77 (0.57–0.88)
Genotype non-A (137) 0.77 (0.73–0.79)
Not available (1105) 0.76 (0.73–0.79)
Viral load (IU/mL) >0.10
<3 Log (276) 0.79 (0.73–0.84)
3–5 Log (115) 0.82 (0.72–0.88)
5–7 Log (330) 0.72 (0.66–0.77)
>7 Log (464) 0.77 (0.72–0.81)
Not available (118) 0.76 (0.65–0.83)
ALT <50 IU/L >0.10
No (825) 0.75 (0.72–0.79)
Yes (478) 0.76 (0.70–0.80)
ALT <25 IU/L >0.10
No (1151) 0.76 (0.73–0.79)
Yes (152) 0.72 (0.57–0.82)
aIn Asian patients (n=546) the overall mean (95% CI) accuracy of FibroTest (standardized using Obuchowski measure) was 0.827 (0.807–0.846),
no different than that of non-Asian (n=757), 0.853 (0.839–0.867), (NS)
bAfrican American also included
cIn 2 patients, status was unknown
dIn patients with presence of HBeAg (n=753) the overall mean (95% CI) accuracy of FibroTest (standardized using Obuchowski measure) was
0.831 (0.814–0.848), no different than that of patients without HBeAg (n=548), 0.854 (0.838–0.870), (NS)
eP=0.046 vs “present”
ALT alanine aminotransferase, AUROC area under the receiver operating curve, HBeAg hepatitis B early antigen, HBV hepatitis B virus
Curr Hepatitis Rep (2011) 10:87–97 95particularly for the diagnosis of advanced fibrosis. However,
neither biomarkers nor biopsy are sufficient, alone, to make a
definitive decision in a given patient, and all the clinical and
biological data must be taken into account.
This study reinforced our previous conclusion that,
based on current evidence, a wise recommendation in
patients with CHB would be a moratorium on liver biopsy
as a first-line procedure, while awaiting studies demon-
strating its cost utility versus that of biomarkers [45].
Biopsy as a second-line estimate of liver injury should still
be indicated for intricate disease or clinicobiological
discordances.
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